This inventor holds 4 USPTO granted patents and 1 published patent application. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovative Contributions of XI-Tao Wang
Introduction
XI-Tao Wang is a prominent inventor based in Princeton, NJ (US). He has made significant strides in the field of cancer immunotherapy, particularly through his research on disrupting PD-1/PD-L1 signaling. His work has the potential to transform treatment options for cancer patients.
Latest Patents
XI-Tao Wang holds a patent for "Cancer Immunotherapy by Disrupting PD-1/PD-L1 Signaling." This innovative approach aims to enhance the immune system's ability to fight cancer, offering new hope for effective treatments.
Career Highlights
Currently, XI-Tao Wang is associated with Bristol-Myers Squibb Company, a leading biopharmaceutical firm. His role at the company allows him to contribute to groundbreaking research and development in the field of oncology.
Collaborations
One of his notable collaborators is Stacie M Goldberg, who is also involved in significant research initiatives. Their partnership exemplifies the collaborative spirit in scientific research, particularly in the pursuit of advancements in cancer treatment.
Conclusion
XI-Tao Wang's contributions to cancer immunotherapy highlight the importance of innovation in medical research. His work not only advances scientific knowledge but also offers hope for improved cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile